Spyre Therapeutics (NASDAQ: SYRE) granted stock options to purchase an aggregate of 51,300 shares of common stock to four non-executive employees as equity inducement awards under its 2018 Equity Inducement Plan.
The options have a 10-year term, a $70.54 exercise price, and a time-based vesting schedule tied to continued service.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – SYRE
-2.24%
-2.24%Session close to close
In the Jun 8 session, SYRE declined 2.24%, reflecting a moderate negative market reaction.
This announcement details routine equity inducement awards: 51,300 stock options granted to four non...
Analysis
This announcement details routine equity inducement awards: 51,300 stock options granted to four non-executive employees with a 10-year term, a $70.54 exercise price, and a standard vesting schedule. It follows a series of more material catalysts, including Phase 2 trial progress and substantial equity financings. Investors may focus on how upcoming clinical readouts and the existing $500,000,000 shelf registration interact with Spyre’s cash runway and development plans.
Key Figures
Inducement options:51,300 sharesEmployees granted:4 employeesExercise price:$70.54+5 more
8 metrics
Inducement options51,300 sharesStock options granted to four non-executive employees under 2018 Plan
Employees granted4 employeesRecipients of equity inducement awards
Exercise price$70.54Option strike price equal to June 1, 2026 Nasdaq close
Option term10 yearsContractual life of inducement stock options
Initial vesting25% at 1 yearOne-fourth of shares vest on first anniversary of start date
Ongoing vesting1/48 monthlyRemaining shares vest monthly thereafter, subject to service
Shelf capacity$500,000,000Maximum amount of securities under S-3 shelf registration
ATM program size$154,059,875Common stock available under at-the-market Sales Agreement
Closed underwritten offering of 7,475,000 shares at $62 for $463.5M gross proceeds.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent Spyre news, especially clinical and financing milestones, has generally coincided with positive price reactions, while routine corporate items like inducement awards have seen minimal impact.
Recent Company History
Over the past few months, Spyre has advanced multiple value-driving initiatives. It completed enrollment in the SKYWAY Phase 2 basket trial, with Phase 2 efficacy readouts guided for Q3–Q4 2026. Q1 2026 results highlighted strong SPY001 induction data and a pro forma cash position of $1.1768B following a $463M raise, and a subsequent offering added roughly $463.5M in gross proceeds. Routine items, including prior inducement grants, have historically produced only small price moves compared to clinical and financing catalysts.
Key Terms
equity inducement awards, stock options, exercise price, vesting, +1 more
5 terms
equity inducement awardsfinancial
"shares of common stock of Spyre to four non-executive employees as equity inducement awards under"
Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.
stock optionsfinancial
"approved the grant of stock options to purchase an aggregate of 51,300 shares of common stock"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise pricefinancial
"a 10-year term and an exercise price equal to $70.54, the closing price per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestingfinancial
"options shall vest and become exercisable as to one-fourth (1/4th) of the shares"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Nasdaq Listing Rule 5635(c)(4)regulatory
"material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
WALTHAM, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 51,300 shares of common stock of Spyre to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on June 1, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options were granted with a 10-year term and an exercise price equal to $70.54, the closing price per share of Spyre's common stock as reported by Nasdaq on June 1, 2026. The options granted to the employees shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The stock options are subject to the terms of the 2018 Plan.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
For more information, please visit http://spyre.com.
For Investors: Eric McIntyre SVP of Finance and Investor Relations Spyre Therapeutics Eric.mcintyre@spyre.com
FAQ
What inducement awards did Spyre Therapeutics (NASDAQ: SYRE) grant on June 1, 2026?
Spyre Therapeutics granted stock options for an aggregate of 51,300 common shares to four non-executive employees as equity inducement awards. According to the company, these were issued under its 2018 Equity Inducement Plan, as amended, to support new hires.
What is the exercise price and term of the new Spyre Therapeutics (SYRE) stock options?
The inducement stock options have a 10-year term and an exercise price of $70.54 per share. According to Spyre Therapeutics, this price equals the Nasdaq closing price of its common stock on June 1, 2026, the approval date.
How do Spyre Therapeutics (SYRE) inducement stock options vest for the new employees?
The options vest 25% on the first anniversary of each employee’s start date, then monthly thereafter. According to Spyre Therapeutics, one-forty-eighth of the shares vest every month, subject to continuous service through the applicable vesting dates.
Why did Spyre Therapeutics (SYRE) issue stock options under Nasdaq Listing Rule 5635(c)(4)?
Spyre issued these options as material inducements to new employees, consistent with Nasdaq Listing Rule 5635(c)(4). According to the company, the equity awards supported acceptance of employment and were granted under its 2018 Equity Inducement Plan.
How many employees received Spyre Therapeutics (SYRE) inducement stock options and under which plan?
Four non-executive employees received the inducement stock options. According to Spyre Therapeutics, the grants were made under the Spyre Therapeutics 2018 Equity Inducement Plan, as amended, and are subject to that plan’s terms and conditions.
What is the potential share impact of Spyre Therapeutics (SYRE) granting 51,300 inducement options?
The grants permit purchase of up to 51,300 Spyre common shares if fully exercised. According to Spyre Therapeutics, these options are separate inducement awards for new employees and are subject to a 10-year term and time-based vesting.
